1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Roopa Industries Limited

Roopa Industries Limited

BBSE:ROOPAIND
45.85
INR
+1.95
(+4.44%)
0.16EPS
310.74P/E
399.96MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
36.3
39.38
38.91
38.07
23.32
37.76
34.22
36.16
65.1
96.84
89.54
153.44
162.11
160.65
Basic EPS, GAAP
-2.55
0.2
0.22
0.24
0.69
0.77
0.47
0.91
1.29
1.72
1.93
2.59
0.11
0.16
Free Cash Flow per Basic Share
0.48
0.56
1.62
-1.95
-8.84
2.21
2.47
-1.6
1.91
-2.21
1.55
-9.47
5.25
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
10.79
11
11.52
11.9
12.48
13.25
13.73
14.7
16
17.73
19.67
22.24
22.37
- -
Tangible Book Value per Share
10.79
11
11.52
11.9
12.48
13.25
13.73
14.7
16
17.73
19.67
22.24
22.37
- -
Basic Weighted Avg Shares
8
8
8
8
8
8
8
8
8
8
8
8
8
8
Sales/Revenue/Turnover
286
310
306
299
183
297
269
284
512
762
704
1,207
1,275
1,258
Operating Margin (%)
-2.71
5.17
5.33
7.85
-17.18
6.72
7.46
7.04
5.3
4.39
5.22
2.73
5.94
5.95
Depreciation Expense
6
7
5
5
5
6
8
8
9
9
9
9
8
8
Net Income, GAAP
-20
2
2
2
5
6
4
7
10
13
15
20
1
1
Effective Tax Rate (%)
- -
8.93
35.15
55.92
- -
23.49
53.5
23.2
25.38
25.31
30.12
25.23
50.89
46.4
Profit Margin (%)
-7.03
0.52
0.56
0.63
2.94
2.03
1.38
2.52
1.98
1.77
2.16
1.69
0.07
0.1
Working Capital
17
34
65
101
117
97
86
99
73
29
61
165
128
- -
LT Debt
27
34
49
70
101
95
74
78
41
20
53
64
21
- -
Total Equity
85
87
91
94
98
104
108
116
126
139
155
175
176
- -
Return on Invested Capital (%)
- -
0.98
1.01
1.05
- -
6.13
3.85
6
7.63
8.58
7.03
5.32
3.16
- -
Return on Capital (%)
- -
4.52
4.25
3.53
- -
5.52
3.4
5.67
7.14
8.25
8.08
8.31
2.94
- -
Return on Common Equity (%)
-21.14
1.88
1.94
2.04
5.63
5.97
3.51
6.41
8.41
10.17
10.33
12.34
0.47
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
286
- -
LT Borrowings
- -
21
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
346
308
400

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
632
- -
Cash, Cash Equivalents & STI
- -
15
- -
Accounts Receivable, Net
- -
219
- -
Inventories
- -
308
- -
Total Current Liabilities
- -
504
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
286
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.93%
8.85%
0.58%
Free Cash Flow
-161.7%
-294.27%
-155.43%
Net Income, GAAP
28.8%
5.06%
-95.92%
Sales/Revenue/Turnover
21.56%
39.66%
5.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
345
256
307
298
1,207
2026
351
287
335
301
1,275
2027
333
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.35
0.74
0.97
0.51
2.59
2026
0.36
0.59
0.98
-1.8
0.11
2027
0.43
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tumbalam Gooty Raghavendra
Full Time Employees
56
Sector
Health technology
Industry
Pharmaceuticals: major
Address
6-2-1012, TGV Mansion Hyderabad TS India 500004
IPO Date
May 24, 1995
Website
roopaindustries.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Roopa Industries Limited manufactures and markets active pharmaceutical ingredients, pharmaceutical intermediates, nutraceuticals, bulk drugs, and fine chemicals in India and internationally; core products include triphenyl phosphine for cephalosporin antibiotics, statins, specialty resins, paints, fire retardants, phosphonium salts, phase transfer catalysts, and agricultural applications; glucosamine as a nutritional supplement for arthritis treatment; bromine and its derivatives such as meta bromo anisole, tetra butyl ammonium bromide, 1-bromo-3-chloropropane, and 1-acetoxy ethyl bromide for agro chemicals, dyes, organic and inorganic intermediates, medical and veterinary products, gasoline applications, water purification, disinfectants, insecticides, pesticides, and mercury decontamination; N,N-dicyclohexylcarbodiimide; and 5-cyano phthalide. The company, founded in 1985 and headquartered in Hyderabad, India, with manufacturing facilities in Patancheru and Adoni in Andhra Pradesh, employs over 150 qualified staff including a research and development division and serves global customers with customized requirements through world-class infrastructure. Roopa Industries maintains operations in the chemicals and pharmaceuticals sectors targeting pharmaceutical manufacturers, nutraceutical producers, and industrial chemical users; it recently experienced a fire incident in a storage room for raw materials, work-in-progress, and finished goods at its Patancheru plant on November 3, 2025.